Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine

Ofra Amir; Yair Goldberg; Micha Mandel; Yinon M. Bar-On; Omri Bodenheimer; Nachman Ash; Sharon Alroy-Preis; Amit Huppert; Ron Milo

doi:https://doi.org/10.1038/s41467-022-29578-w

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine

Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Nachman Ash, Sharon Alroy-Preis, Amit Huppert, Ron Milo

Technion - Israel Institute of Technology, Tel Aviv University, Weizmann Institute of Science, The Hebrew University of Jerusalem

Research output: Contribution to journal › Article › peer-review

Abstract

Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a “fresh” booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12–14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16–18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.

Original language	English
Article number	1971
Journal	Nature Communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-022-29578-w
State	Published - 1 Dec 2022

All Science Journal Classification (ASJC) codes

General Chemistry
General
General Biochemistry,Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

https://doi.org/10.1038/s41467-022-29578-w

Cite this

@article{71ad557634bf4167b38bedc7614c7606,

title = "Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine",

abstract = "Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a “fresh” booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12–14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16–18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.",

author = "Ofra Amir and Yair Goldberg and Micha Mandel and Bar-On, {Yinon M.} and Omri Bodenheimer and Nachman Ash and Sharon Alroy-Preis and Amit Huppert and Ron Milo",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

day = "1",

doi = "https://doi.org/10.1038/s41467-022-29578-w",

language = "الإنجليزيّة",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine

AU - Amir, Ofra

AU - Goldberg, Yair

AU - Mandel, Micha

AU - Bar-On, Yinon M.

AU - Bodenheimer, Omri

AU - Ash, Nachman

AU - Alroy-Preis, Sharon

AU - Huppert, Amit

AU - Milo, Ron

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a “fresh” booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12–14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16–18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.

AB - Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a “fresh” booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12–14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16–18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.

UR - http://www.scopus.com/inward/record.url?scp=85128304908&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41467-022-29578-w

DO - https://doi.org/10.1038/s41467-022-29578-w

M3 - مقالة

C2 - 35418201

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 1971

ER -

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this